PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors
暂无分享,去创建一个
Samuel Singer | Jonathan A. Fletcher | J. Fletcher | G. Demetri | S. Singer | M. Heinrich | C. Corless | C. Fletcher | Chang-jie Chen | D. Griffith | A. Town | L. McGreevey | A. Duensing | George D. Demetri | Ajia Town | Anette Duensing | Christopher D. M. Fletcher | Diana J. Griffith | Michael C. Heinrich | Laura McGreevey | Christopher L. Corless | Chang-Jie Chen | Nora Joseph | Andrea Haley | Nora E. Joseph | A. Haley | Laura S. McGreevey | Ajia Town | Andrea Haley
[1] B. Druker,et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. , 2000, The Journal of pharmacology and experimental therapeutics.
[2] Y. Ma,et al. Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. , 2001, Leukemia research.
[3] S. Hirota,et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. , 1999, Cancer research.
[4] J. Fletcher,et al. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. , 2002, Human pathology.
[5] A. D. Van den Abbeele,et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.
[6] S. Hirota,et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.
[7] T. Jacks,et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications , 2001, Oncogene.
[8] W. Hiddemann,et al. A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia. , 2002, Blood.
[9] C. Moskaluk,et al. Activating c-kit gene mutations in human germ cell tumors. , 1999, The American journal of pathology.
[10] M. Israel,et al. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. , 2002, Cancer research.
[11] Nicholas C P Cross,et al. The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. , 2002, Human molecular genetics.
[12] John Malysz,et al. W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity , 1995, Nature.
[13] S. Hubbard,et al. Identification of substituted 3-[(4,5,6, 7-tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rbeta tyrosine kinases. , 2000, Journal of medicinal chemistry.
[14] Y. Suzuki,et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[15] C. J. Chen,et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. , 2001, Cancer research.
[16] T. Naoe,et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. , 2001, Blood.
[17] J. Lasota,et al. Gastrointestinal stromal tumors – definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis , 2000, Virchows Archiv.
[18] Sigrid Stroobants,et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study , 2001, The Lancet.